Utilising organs from hepatitis C virus PCR-positive donors in Western Australia

Peter Boan; Jagadish Jamboti; Michael Musk; Melanie Lavender; Jeremy P Wrobel; Felicity Lee; Amit Shah; Lynette A Pereira; J Owen Robinson; Ashley Irish

doi:10.1111/imj.16345

Utilising organs from hepatitis C virus PCR-positive donors in Western Australia

Intern Med J. 2024 Apr;54(4):678-681. doi: 10.1111/imj.16345. Epub 2024 Mar 7.

Authors

Peter Boan^{1

2}, Jagadish Jamboti^{3

4

5}, Michael Musk⁶, Melanie Lavender⁶, Jeremy P Wrobel^{6

7}, Felicity Lee⁸, Amit Shah⁸, Lynette A Pereira^{1

2

9}, J Owen Robinson^{1

2

9}, Ashley Irish³

Affiliations

¹ Department of Infectious Diseases, Fiona Stanley Hospital, Perth, Western Australia, Australia.
² Department of Microbiology, Fiona Stanley Hospital, PathWest Laboratory Medicine Western Australia, Perth, Western Australia, Australia.
³ Department of Nephrology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
⁴ School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
⁵ School of Medicine, Curtin University, Perth, Western Australia, Australia.
⁶ Advanced Lung Disease Unit, Fiona Stanley Hospital, Perth, Western Australia, Australia.
⁷ Department of Medicine, University of Notre Dame Australia, Perth, Western Australia, Australia.
⁸ Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Perth, Western Australia, Australia.
⁹ Department of Infectious Disease, Royal Perth Hospital, Perth, Western Australia, Australia.

PMID: 38450913
DOI: 10.1111/imj.16345

Abstract

We transplanted six solid organs from three hepatitis C virus (HCV) polymerase chain reaction (PCR)-positive donors during 2018-2023. Recipients were treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 4-12 weeks, with all six achieving sustained virological response without significant adverse events. As occurs in other jurisdictions, solid organ transplants from HCR PCR-positive donors can be safely utilised in Australia.

Keywords: HCV; donor‐derived infection; hepatitis C virus; transplantation.

MeSH terms

Antiviral Agents / therapeutic use
Hepacivirus / genetics
Hepatitis C* / diagnosis
Hepatitis C* / drug therapy
Hepatitis C, Chronic* / drug therapy
Humans
Polymerase Chain Reaction
Sofosbuvir / therapeutic use
Tissue Donors
Western Australia / epidemiology

Substances

Antiviral Agents
Sofosbuvir